IL15RA drives antagonistic mechanisms of cancer development and immune control in lymphocyte-enriched triple-negative breast cancers

Cancer Research

Volumn 74, Issue 17, 2014, Pages 4908-4921

  Marra, Pierfrancesco ^a   Mathew, Sumi ^a   Grigoriadis, Anita ^a   Wu, Yin ^a   Kyle Cezar, Fernanda ^a   Watkins, Johnathan ^a   Rashid, Mamunur ^b   De Rinaldis, Emanuele ^c   Hessey, Sonya ^a   Gazinska, Patrycja ^a   Hayday, Adrian ^a   Tutt, Andrew ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^c GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IL15 PROTEIN, HUMAN; IL15RA PROTEIN, HUMAN; INTERLEUKIN 15; INTERLEUKIN 15 RECEPTOR;

ANIMAL; APOPTOSIS; CELL MOTION; CELL PROLIFERATION; FEMALE; GENETICS; HUMAN; IMMUNOLOGY; LYMPHOCYTE; MONONUCLEAR CELL; MOUSE; PARACRINE SIGNALING; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST CANCER; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; HUMANS; INTERLEUKIN-15; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTES; MICE; PARACRINE COMMUNICATION; RECEPTORS, INTERLEUKIN-15; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84907063090     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-0637     Document Type: Article

References (50)

1. Galon J, Angell HK, Bedognetti D, Marincola FM. The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity 2013;39:11-26.
2. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008;454:436-44.
3. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011;331:1565-70.
4. Denkert C, Loibl S, Noske A, Roller M, Muller BM, Komor M, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2010;28:105-13.
5. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000;406: 747-52.
6. Comprehensive molecular portraits of human breast tumours. Nature 2012;490:61-70.
7. Reis-Filho JS, Pusztai L. Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet 378:1812-23.
8. Irshad S, Grigoriadis A, Lawler K, Ng T, Tutt A. Profiling the immune stromal interface in breast cancer and its potential for clinical impact. Breast Care 2012;7:273-80.
9. Rakha EA, Ellis IO, Reis-Filho JS. Immunohistochemical heterogeneity of breast carcinomas negative for estrogen receptors, progesterone receptors and Her2/neu (basal-like breast carcinomas). Mod Pathol 2008;21:1060-1.
10. Sabatier R, Finetti P, Cervera N, Lambaudie E, Esterni B, Mamessier E, et al. A gene expression signature identifies two prognostic subgroups of basal breast cancer. Breast Cancer Res Treat 2011;126:407-20.
11. Rakha EA, Aleskandarany M, El-Sayed ME, Blamey RW, Elston CW, Ellis IO, et al. The prognostic significance of inflammation and medullary histological type in invasive carcinoma of the breast. Eur J Cancer 2009;45:1780-7.
12. Bertucci F, Finetti P, Cervera N, Charafe-Jauffret E, Mamessier E, Adelaide J, et al. Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. Cancer Res 2006; 66:4636-44.
13. Waldmann T. The contrasting roles of IL2 and IL15 in the life and death of lymphocytes: implications for the immunotherapy of rheumatological diseases. Arthritis Res 2002;4:S161-7.
14. Budagian V, Bulanova E, Paus R, Bulfone-Paus S. IL15/IL15 receptor biology: a guided tour through an expanding universe. Cytokine Growth Factor Rev 2006;17:259-80.
15. Lodolce J, Burkett P, Koka R, Boone D, Chien M, Chan F, et al. Interleukin-15 and the regulation of lymphoid homeostasis. Mol Immunol 2002;39:537-44.
16. Becknell B, Caligiuri MA. Interleukin-2, interleukin-15, and their roles in human natural killer cells. Adv Immunol 2005;86:209-39.
17. Bulfone-Paus S, Ungureanu D, Pohl T, Lindner G, Paus R, Ruckert R, et al. Interleukin-15 protects from lethal apoptosis in vivo. Nat Med 1997;3:1124-8.
18. Tejman-Yarden N, Zlotnik M, Lewis E, Etzion O, Chaimovitz C, Douvdevani A. Renal cells express a functional interleukin-15 receptor. Nephrol, Dial, Transplant 2005;20:516-23.
19. Pereno R, Giron-Michel J, Gaggero A, Cazes E, Meazza R, Monetti M, et al. IL15/IL15Ralpha intracellular trafficking in human melanoma cells and signal transduction through the IL15Ralpha. Oncogene 2000;19: 5153-62.
20. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Investigation 2011;121:2750-67.
21. de Rinaldis E, Gazinska P, Mera A, Modrusan Z, Fedorowicz GM, Burford B, et al. Integrated genomic analysis of triple-negative breast cancers reveals novel microRNAs associated with clinical and molecular phenotypes and sheds light on the pathways they control. BMC Genomics 2013;14:643.
22. Rasmussen M, Sundstrom M, Goransson Kultima H, Botling J, Micke P, Birgisson H, et al. Allele-specific copy number analysis of tumor samples with aneuploidy and tumor heterogeneity. Genome Biol 2011; 12:R108.
23. Curtis C, Shah SP, Chin S-F, Turashvili G, Rueda OM, Dunning MJ, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012;486:346-52.
24. Karn T, Pusztai L, Holtrich U, Iwamoto T, Shiang CY, Schmidt M, et al. Homogeneous datasets of triple negative breast cancers enable the identification of novel prognostic and predictive signatures. PloS ONE 2011;6:e28403.
25. Grigoriadis A, Mackay A, Noel E, Wu PJ, Natrajan R, Frankum J, et al. Molecular characterisation of cell line models for triple-negative breast cancers. BMC Genomics 2012;13:619.
26. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer cell 2006;10:515-27.
27. Gazinska P, Grigoriadis A, Brown JP, Millis RR, Mera A, Gillett CE, et al. Comparison of basal-like triple-negative breast cancer defined by morphology, immunohistochemistry and transcriptional profiles. Mod Pathol 2013;26:955-66.
28. Chen X, Fau - Li J, Li J, Fau - Gray WH, Gray WH, Fau - Lehmann BD, et al. TNBCtype: a subtyping tool for triple-negative breast cancer.
29. Cariati M, Marlow R, Dontu G. Xenotransplantation of breast cancers. Methods in Mol Biology 2011;731:471-82.
30. Duitman EH, Orinska Z, Bulanova E, Paus R, Bulfone-Paus S. How a cytokine is chaperoned through the secretory pathway by complexing with its own receptor: lessons from interleukin-15 (IL15)/IL15 receptor alpha. Mol Cell Biol 2008;28:4851-61.
31. Johnston JA, Bacon CM, Finbloom DS, Rees RC, Kaplan D, Shibuya K, et al. Tyrosine phosphorylation and activation of STAT5, STAT3, and Janus kinases by interleukins 2 and 15. Proc Natl Acad Sci U S A 1995;92:8705-9.
32. Masuda A, Matsuguchi T, Yamaki K, Hayakawa T, Kubo M, LaRochelle WJ, et al. Interleukin-15 induces rapid tyrosine phosphorylation of STAT6 and the expression of interleukin-4 in mouse mast cells. J Biol Chem 2000;275:29331-7.
33. Malilas W, Koh SS, Kim S, Srisuttee R, Cho IR, Moon J, et al. Cancer upregulated gene 2, a novel oncogene, enhances migration and drug resistance of colon cancer cells via STAT1 activation. Int J Oncol 2013;43:1111-6.
34. Su AI, Wiltshire T, Batalov S, Lapp H, Ching KA, Block D, et al. A gene atlas of the mouse and human protein-encoding transcriptomes. Proc Natl Acad Sci U S A 2004;101:6062-7.
35. Tinhofer I, Marschitz I, Henn T, Egle A, Greil R. Expression of functional interleukin-15 receptor and autocrine production of interleukin-15 as mechanisms of tumor propagation in multiple myeloma. Blood 2000; 95:610-8.
36. Dobbeling U, Dummer R, Laine E, Potoczna N, Qin JZ, Burg G. Interleukin-15 is an autocrine/paracrine viability factor for cutaneous T-cell lymphoma cells. Blood 1998;92:252-8.
37. Lai YG, Hou MS, Lo A, Huang ST, Huang YW, Yang-Yen HF, et al. IL15 modulates the balance between Bcl-2 and Bim via a Jak3/1-PI3K-Akt- ERK pathway to promote CD8alphaalpha+ intestinal intraepithelial lymphocyte survival. Eur J Immunol 2013;43:2305-16.
38. McDonald PP, Russo MP, Ferrini S, Cassatella MA. Interleukin-15 (IL15) induces NF-kappaB activation and IL8 production in human neutrophils. Blood 1998;92:4828-35.
39. Chenoweth MJ, Mian MF, Barra NG, Alain T, Sonenberg N, Bramson J, et al. IL15 can signal via IL15Ralpha, JNK, and NF-kappaB to drive RANTES production by myeloid cells. J Immunol 2012;188:4149-57.
40. Ratthe C, Girard D. Interleukin-15 enhances human neutrophil phagocytosis by a Syk-dependent mechanism: importance of the IL15Ralpha chain. J leukocyte Biol 2004;76:162-8.
41. Stevens AC, Matthews J, Andres P, Baffis V, Zheng XX, Chae DW, et al. Interleukin-15 signals T84 colonic epithelial cells in the absence of the interleukin-2 receptor beta-chain. The Am J Physiol 1997;272:G1201-8.
42. Aksamitiene E, Kholodenko BN, Kolch W, Hoek JB, Kiyatkin A. PI3K/ Akt-sensitive MEK-independent compensatory circuit of ERK activation in ER-positive PI3K-mutant T47D breast cancer cells. Cell Signal 2010;22:1369-78.
43. Haar EV, Lee S-i, Bandhakavi S, Griffin TJ, KimD-H. Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40. Nat Cell Biol 2007;9:316-23.
44. Morgensztern D, McLeod HL. PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs 2005;16:797-803.
45. Andl CD, Mizushima T, Oyama K, Bowser M, Nakagawa H, Rustgi AK. EGFR-induced cell migration is mediated predominantly by the JAKSTAT pathway in primary esophageal keratinocytes. Am J Physiol Gastrointest Liver Physiol 2004;287:G1227-37.
46. Hartman ZC, Poage GM, den Hollander P, Tsimelzon A, Hill J, Panupinthu N, et al. Growth of triple-negative breast cancer cells relies upon coordinate autocrine expression of the proinflammatory cytokines IL6 and IL8. Cancer Res 2013;73:3470-80.
47. Tao QS, Huang HL, Chai Y, Luo X, Zhang XL, Jia B, et al. Interleukin-6 upregulates the expression of interleukin-15 is associated with MAPKs and PI3-K signaling pathways in the human keratinocyte cell line, HaCaT. Mol Biol Reports 2012;39:4201-5.
48. Roberts AI, Lee L, Schwarz E, Groh V, Spies T, Ebert EC, et al. NKG2D receptors induced by IL15 costimulate CD28-negative effector CTL in the tissue microenvironment. J Immunol 2001;167:5527-30.
49. Ma A, Koka R, Burkett P. Diverse functions of IL2, IL15, and IL7 in lymphoid homeostasis. Ann Rev Immunol 2006;24:657-79.
50. Sutherland CL, Rabinovich B, Chalupny NJ, Brawand P, Miller R, Cosman D. ULBPs, human ligands of the NKG2D receptor, stimulate tumor immunity with enhancement by IL15. Blood 2006;108:1313-9.